Abbott Laboratories (NYSE:ABT) Updates Q3 2026 Earnings Guidance

Abbott Laboratories (NYSE:ABT) issued an update on its third quarter 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 1.380-1.46 for the period, compared to the consensus EPS estimate of 1.420. The company issued revenue guidance of -. Abbott Laboratories also updated its FY 2026 guidance to 5.450-5.60 EPS.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $89.27 on Thursday. The company has a 50 day moving average price of $89.33 and a 200 day moving average price of $102.36. The firm has a market capitalization of $155.49 billion, a P/E ratio of 25.01, a PEG ratio of 1.53 and a beta of 0.61. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. The company had revenue of $12.51 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Royal Bank Of Canada reduced their target price on Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Stifel Nicolaus dropped their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Citigroup reduced their price objective on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Wells Fargo & Company decreased their target price on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Finally, TD Cowen dropped their target price on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $117.61.

Insider Activity at Abbott Laboratories

In related news, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the transaction, the chief financial officer owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction on Monday, April 27th. The stock was bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the transaction, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is currently owned by company insiders.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Analysts expect Abbott’s upcoming Q2 results to show healthy revenue and earnings growth, supported by strong performance in Diagnostics, Devices and Emerging Pharmaceutical/EPD segments. Abbott Laboratories Q2 preview: Analysts see healthy growth backed by Exact Sciences acquisition
• Positive Sentiment: Coverage around Abbott’s cancer diagnostics strategy highlights longer-term growth potential, with management continuing to invest in improving tests and expanding the business after the Exact Sciences acquisition. Abbott’s cancer diagnostics vision: ‘There’s always a hunger to make these tests better’
• Positive Sentiment: Analysts are still recommending investors retain Abbott shares for now, citing emerging-market pharmaceutical growth and continued innovation in nutrition as potential supports for the stock. Reasons to Retain Abbott Stock in Your Portfolio for Now
• Neutral Sentiment: Market commentary says Abbott is one of the names investors are watching as earnings season begins, but the article is mainly a watchlist note rather than fresh company-specific news. UnitedHealth, Abbott Laboratories And 3 Stocks To Watch Heading Into Thursday
• Neutral Sentiment: Another brief market note also flags Abbott ahead of earnings, reinforcing that the stock is being traded around the upcoming results. UnitedHealth, Abbott Laboratories And 3 Stocks To Watch Heading Into Thursday
• Negative Sentiment: Risks remain from macro pressure and foreign exchange swings, which could weigh on results even if core business trends stay healthy. Reasons to Retain Abbott Stock in Your Portfolio for Now
• Negative Sentiment: Nutrition remains a drag in the near term, and some coverage notes that this segment could limit upside if other divisions do not fully offset it. Abbott’s Q2 Earnings on Deck: How Should You Play the Stock Now?

Institutional Trading of Abbott Laboratories

Institutional investors and hedge funds have recently modified their holdings of the stock. Intesa Sanpaolo Wealth Management acquired a new position in shares of Abbott Laboratories during the 4th quarter worth about $29,000. SWAN Capital LLC boosted its holdings in Abbott Laboratories by 53.1% in the 4th quarter. SWAN Capital LLC now owns 300 shares of the healthcare product maker’s stock worth $38,000 after buying an additional 104 shares during the last quarter. Turning Point Benefit Group Inc. purchased a new stake in Abbott Laboratories during the 3rd quarter worth approximately $39,000. Wealth Watch Advisors INC raised its holdings in shares of Abbott Laboratories by 121.6% during the fourth quarter. Wealth Watch Advisors INC now owns 359 shares of the healthcare product maker’s stock valued at $45,000 after acquiring an additional 197 shares during the last quarter. Finally, Swiss RE Ltd. purchased a new position in shares of Abbott Laboratories in the fourth quarter valued at approximately $49,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.